Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Rating of “Moderate Buy” from Analysts

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) has been given a consensus recommendation of “Moderate Buy” by the five brokerages that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $11.6667.

Separately, Weiss Ratings raised shares of Acrivon Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th.

Institutional Trading of Acrivon Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Jane Street Group LLC lifted its position in shares of Acrivon Therapeutics by 18.3% in the fourth quarter. Jane Street Group LLC now owns 342,071 shares of the company’s stock valued at $824,000 after buying an additional 52,823 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Acrivon Therapeutics by 504.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 119,422 shares of the company’s stock worth $288,000 after acquiring an additional 99,680 shares during the last quarter. Geode Capital Management LLC raised its stake in Acrivon Therapeutics by 3.2% in the 4th quarter. Geode Capital Management LLC now owns 198,223 shares of the company’s stock valued at $478,000 after acquiring an additional 6,190 shares during the period. Algert Global LLC bought a new stake in Acrivon Therapeutics in the 3rd quarter valued at $81,000. Finally, Two Sigma Investments LP lifted its holdings in Acrivon Therapeutics by 76.2% during the 3rd quarter. Two Sigma Investments LP now owns 319,205 shares of the company’s stock valued at $578,000 after purchasing an additional 138,033 shares during the last quarter. Institutional investors own 71.62% of the company’s stock.

Acrivon Therapeutics Stock Down 0.6%

NASDAQ:ACRV opened at $1.67 on Friday. Acrivon Therapeutics has a twelve month low of $1.20 and a twelve month high of $3.56. The firm has a market capitalization of $71.48 million, a price-to-earnings ratio of -0.83 and a beta of 1.82. The stock’s 50 day moving average price is $1.68 and its two-hundred day moving average price is $1.72.

Acrivon Therapeutics (NASDAQ:ACRV) last released its earnings results on Wednesday, May 13th. The company reported ($0.49) earnings per share for the quarter, meeting the consensus estimate of ($0.49). As a group, analysts anticipate that Acrivon Therapeutics will post -1.92 earnings per share for the current year.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.